Trials / Conditions / Hypothalamic Obesity

Hypothalamic Obesity

20 registered clinical trials studyying Hypothalamic Obesity — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) NCT07156578	Rhythm Pharmaceuticals, Inc.	Phase 2
Recruiting	A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) NCT06760546	Rhythm Pharmaceuticals, Inc.	Phase 3
Recruiting	Tirzepatide in PWS, HO and GNSO NCT06901245	Grace Kim	Phase 4
Recruiting	Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity NCT06299891	Seattle Children's Hospital	Phase 2
Completed	A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity NCT06046443	Rhythm Pharmaceuticals, Inc.	Phase 2
Recruiting	A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment NCT06239116	Rhythm Pharmaceuticals, Inc.	Phase 1 / Phase 2
Active Not Recruiting	A Trial of Setmelanotide in Acquired Hypothalamic Obesity NCT05774756	Rhythm Pharmaceuticals, Inc.	Phase 3
Unknown	The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study NCT06217848	Seoul National University Hospital	EARLY_Phase 1
Completed	Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) NCT05319301	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	N/A
Withdrawn	Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) NCT05147415	Saniona	Phase 2
Completed	Open-Label Study of Setmelanotide in Hypothalamic Obesity NCT04725240	Rhythm Pharmaceuticals, Inc.	Phase 2
Withdrawn	Neuromodulation for Hypothalamic Obesity NCT03708913	University of British Columbia	N/A
Completed	Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy NCT02860923	University Hospital, Bordeaux	Phase 3
Completed	Intranasal Oxytocin in Hypothalamic Obesity NCT02849743	Shana McCormack, MD	Phase 2
Completed	A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity NCT03673813	Assistance Publique - Hôpitaux de Paris	—
Completed	Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity NCT02664441	Seattle Children's Hospital	Phase 3
Unknown	Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage NCT01783717	Huashan Hospital	N/A
Completed	Effects of Exenatide on Hypothalamic Obesity NCT01061775	Children's Hospitals and Clinics of Minnesota	Phase 1 / Phase 2
Completed	Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Th NCT00892073	The Hospital for Sick Children	Phase 2
Completed	A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients NCT00171613	Novartis	Phase 4